Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Expert Perspectives on the Treatment of Advanced Clear Cell Renal Cell Carcinoma : Episode 11

Managing TKI-Related Adverse Events in RCC

May 23, 2023
By Elizabeth Wulff-Burchfield, MD
Rana R. McKay, MD
  • Pedro C. Barata, MD, MSc
  • Bradley McGregor, MD

Video

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

EP: 1.Overview of Renal Cell Carcinoma and Case of a 61-Year-Old Man with Metastatic Clear Cell RCC

EP: 2.Molecular Testing and Risk Stratification in Advanced Clear Cell RCC

EP: 3.IO-TKI Regimens in Advanced RCC: Recent Data Updates

EP: 4.Selecting the Appropriate IO-TKI in Frontline Setting in Advanced RCC

EP: 5.Selecting the Optimal Treatment Regimen for Favorable-Risk RCC

EP: 6.IO-TKI Regimens in Advanced RCC: Does the Choice of TKI Matter?

EP: 7.Treatment Options in Advanced RCC in the Second-Line Setting

EP: 8.Patient Profile 2: A 59-Year-Old Woman with Advanced Renal Cell Carcinoma

EP: 9.Role of Radiation in the Treatment of RCC

EP: 10.IO-IO Regimens in Advanced RCC: Recent Data Updates

Now Viewing

EP: 11.Managing TKI-Related Adverse Events in RCC

EP: 12.Managing Immune-Related Adverse Events in RCC

EP: 13.COSMIC-313 and Role of Triplet Regimens in Frontline Setting in Advanced RCC

EP: 14.Clinical Pearls for Community Oncologists Treating RCC

Transcript:

Elizabeth Wulff-Burchfield, MD: Dr McGregor, [I’ll] throw it to you. And again, everyone has provided such meaningful advice. Advice is the wrong word, but rather, a window into your own practices and interpretations of the data. One question I hear sometimes from colleagues who don’t treat a great deal of renal cell carcinoma is concern about immune-related adverse events [AEs] when considering nivolumab and ipilimumab. When I let that percolate a bit, it does make me think are there concerns about specific adverse events, or is it more about burden of toxicity overall that might factor into decision-making? Is there any patient profile for whom you’re really trying to avoid certain outcomes, besides [patients] who maybe have autoimmune disease? [Are there] any ways that AEs or toxicity factors in, except for the duration of exposure with TKIs [tyrosine kinase inhibitors]?

Bradley McGregor, MD: Yes, it’s a great question. What I would highlight is that we look at this here, and if we go back to that initial slide, one of the options was single-agent cabozantinib. We haven’t talked about that. I think that’s because, at the end of the day, the combination therapies are important in intermediate- and poor-risk disease. Cabozantinib showed improvement in PFS [progression-free survival] vs sunitinib. That was done in the era before combination therapies, so ultimately a combination therapy is my go-to. We can argue all day about ipilimumab vs IO [immunotherapy]-TKI, and which IO-TKI [should we use], but I don’t think anyone would disagree that in a patient who’s eligible for IO therapy, we should use something IO-based for these patients.

Then to the toxicity point, I think it is a real concern. The one factor that doesn’t get highlighted in the nivolumab-ipilimumab data is those rare but catastrophic issues. So those things that don’t show up, [such as] myocarditis, hypophysitis, adrenal sufficiency, or pancreatitis. Yes, these are rare, less than 1% or 2%, but they can happen with nivolumab-ipilimumab. And some of these endocrine toxicities can be lifelong because they’re not reversible. That being said, often we just treat the endocrine toxicity. If you look at the toxicities in general, large picture, the rates of immune-related adverse events, the need for high-dose steroids is about 30% with nivolumab-ipilimumab. It’s very similar in a lot of the IO-TKI combinations, anywhere from 20% to 30%.

So we’re dealing with immune-related adverse events in both IO-IO and IO-TKI. Overall with IO-IO it’s a bit simpler because when you have toxicity you know it’s the IO, and you can manage appropriately. When you have an IO-TKI, you have all of these overlapping toxicities like liver issues or diarrhea, so it’s a matter of holding the TKI and seeing how things go in that regard. But I think the biggest factor is, yes, there are those rare but significant toxicities with IO-IO, which I tell my patients about. Fortunately, they are very rare, and that’s likely why we see this marked difference in quality of life with nivolumab-ipilimumab vs sunitinib.

Elizabeth Wulff-Burchfield, MD: Those are so hard to counsel patients about. Just the unpredictability of IO therapies is such a difficult communication conundrum, at least for me. I’ll put in a little plug for the ATRIUM trial, which is looking at abatacept as an intervention for immune-mediated myocarditis. It’s already included as one of the options in the guidelines, but that trial is ongoing, and I hope people will open it and contribute to it because I think we need to know the answer to that.

Transcript edited for clarity.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content

Ensuring Response and Tolerable Dose Are Crucial in RCC

Ensuring Response and Tolerable Dose Are Crucial in RCC

Targeted Oncology Staff
May 6th 2025
Article

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.

Read More


Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD
March 1st 2024
Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen


Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC

Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC

Targeted Oncology Staff
April 24th 2025
Article

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.

Read More


Beyond the First-Line: Economides on Advancing Therapies in RCC

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD
February 1st 2024
Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen


Voss Examines TKI/IO and IO/IO  Regimens in Non–Clear Cell RCC

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Targeted Oncology Staff
April 18th 2025
Article

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.

Read More


Participants Explain Rationale for Different IO/TKI Options for ccRCC

Participants Explain Rationale for Different IO/TKI Options for ccRCC

Targeted Oncology Staff
April 15th 2025
Article

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.

Read More

Related Content

Ensuring Response and Tolerable Dose Are Crucial in RCC

Ensuring Response and Tolerable Dose Are Crucial in RCC

Targeted Oncology Staff
May 6th 2025
Article

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.

Read More


Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD
March 1st 2024
Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen


Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC

Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC

Targeted Oncology Staff
April 24th 2025
Article

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.

Read More


Beyond the First-Line: Economides on Advancing Therapies in RCC

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD
February 1st 2024
Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen


Voss Examines TKI/IO and IO/IO  Regimens in Non–Clear Cell RCC

Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC

Targeted Oncology Staff
April 18th 2025
Article

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.

Read More


Participants Explain Rationale for Different IO/TKI Options for ccRCC

Participants Explain Rationale for Different IO/TKI Options for ccRCC

Targeted Oncology Staff
April 15th 2025
Article

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.